Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm thinking you have been wrong for 6 weeks now so why should I listen to you? I'm also thinking as with any EPIC STOCK, AMBS will continue marching higher and higher much to the chagrin of everyone that has sold. This will be a 100 to 200 bagger from the bottom. Do the math on that and you'll see that this has a lot more room to go higher.
It isn't every day that you get the Co Founder of Amgen presenting on your behalf about commercial opportunities of your drug and saying that "it could be the biggest success I have ever seen." All this with patent protection on anything with 90% homology (i.e., similarity) to MANF...patents which were recently upheld after being challenged by another biotech company in the same exact field and with funding from the Michael J. Fox Foundation.
January 8th is coming fast. Only the strong (i.e., patient) will be rich.
Epic Stocks drop fast and scare people only to have them regret selling a day or two later. AMBS is an EPIC STOCK...ie a stock that comes around once every 5 to 10 years. People have been bashing for weeks and yet with every pullback the stock bottoms out at higher and higher levels and anyone that listened to those people were left waiting for an entry price that never happened. It will ultimately be a 100 to 200 bagger for those that got in at $0.005 and held on. Do the math: it's going to $0.50 to $1.00.
For people like me who got in around .025 I will only book a 20 to 40 bagger. The patient ones will make out like bandits.
Stars are aligned for a move to $0.40 shortly. The market cap at $21 million is way too small for this given:
+Money poured into GDNF (which has had worse results than MANF) ~ $250 Million
+Money poured into Neurturin ~ $150 Million
+Patent protection - upheld in court vs Hermo Pharma, a VC backed and MJFF funded biotech firm
+Founder of Amgen believes it could be the biggest success he has ever seen.
Yep...it's an epic stock. 100 to 200 bagger from the 0.005 area. Just buy and hold if you want to be wealthy.
They call this an EPIC STOCK...ie a stock that comes around once every 5 to 10 years. People have been bashing for weeks and yet with every pullback the stock bottoms out at higher and higher levels and anyone that listened to those people were left waiting for an entry price that never happened. It will ultimately be a 100 to 200 bagger for those that got in at $0.005 and held on. Do the math: it's going to $0.50 to $1.00.
For people like me who got in around .025 I will only book a 20 to 40 bagger. The patient ones will make out like bandits.
Stars are aligned for a move to $0.40 shortly. The market cap at $21 million is way too small for this given:
+Money poured into GDNF (which has had worse results than MANF) ~ $250 Million
+Money poured into Neurturin ~ $150 Million
+Patent protection - upheld in court vs Hermo Pharma, a VC backed and MJFF funded biotech firm
+Founder of Amgen believes it could be the biggest success he has ever seen.
This is an epic stock...ie a stock that comes around once every 5 to 10 years. People have been bashing for weeks and yet with every pullback the stock bottoms out at higher and higher levels and anyone that listened to them were left waiting for an entry price that never happened. It will ultimately be a 100 to 200 bagger for those that got in at $0.005 and held on. For people like me who got in around .025 I will only book a 20 to 40 bagger. The patient ones will make out like bandits.
Stars are aligned for a move to $0.40. The market cap at $21 million is way too small for this given:
+Money poured into GDNF (which has had worse results than MANF) ~ $250 Million
+Money poured into Neurturin ~ $150 Million
+Patent protection - upheld in court vs Hermo Pharma, a VC backed and MJFF funded biotech firm
+Founder of Amgen believes it could be the biggest success he has ever seen.
The 1/8/13 conference will be a major catalyst. Having the founder of a $67 billion company presenting on your behalf about the commercial opportunities of your drug should add just a teeny weeny amount of credibility.
Ask yourself 2 simple questions:
(1) Why is the co-founder of Amgen saying MANF "could be one of the biggest successes that I have ever seen."? This is a 79 year old man that has seen a lot of things in his career.
(2) Why did Hermo Pharma, a MJFF grant recipient and VC backed, feel compelled to challenge the company's MANF patents?
Don't think they have what it takes to make it through trials? I believe the execs from Amgen, Bayer, Bristol Myers, and Pfizer have what it takes to get them a partnership and licensing deal. Those of us that are patient enough to sit through pullbacks will be rewarded immensely.
I'm putting my money with the co-founder of Amgen, not some college kids on this board with $3,000 who are naive enough to think they have any power over a stock.
I enjoyed your novel I especially liked the part about conspiracy theories and spreading fears about dilution. Best of luck to you as I have said before this will be going to $.40 and those that are patient will make out like bandits
Stars are aligned for a move to $0.40. The market cap at $17 million is way too small for this given:
+Money poured into GDNF (which has had worse results than MANF) ~ $250 Million
+Money poured into Neurturin ~ $150 Million
+Patent protection - upheld in court vs Hermo Pharma, a VC backed and MJFF funded biotech firm
+Founder of Amgen believes it could be the biggest success he has ever seen.
This is an epic stock...ie a stock that comes around once every 5 to 10 years. People like Solantey or any variation of him have been bashing for weeks and yet with every pullback the stock bottoms out at higher and higher levels and anyone that listened to them were left waiting for an entry price that never happened. It will ultimately be a 100 to 200 bagger for those that got in and held on. For people like me who got in around .025 I will only book a 20 to 40 bagger. The patient ones will make out like bandits.
The 1/8/13 conference will be a major catalyst. Having the founder of a $67 billion company presenting on your behalf about the commercial opportunities of your drug should add just a teeny weeny amount of credibility.
Ask yourself 2 simple questions:
(1) Why is the co-founder of Amgen saying MANF "could be one of the biggest successes that I have ever seen."? This is a 79 year old man that has seen a lot of things in his career.
(2) Why did Hermo Pharma, a MJFF grant recipient and VC backed, feel compelled to challenge the company's MANF patents?
MANF is producing much better results than GDNF produced at this stage and GDNF was purchased for over $250 Million AT THIS STAGE of testing.
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
AMBS is only worth $17 Million right now.
Versus $250 Million.
Do the math. Listen to people that know the science like Dr. Rubinfeld and the dozens of other scientists that have worked on MANF over the past 10 years (just google MANF if you don't believe me). AMBS has patent protection on MANF and anything that has a 90% homology (i.e., similarity) to MANF. These proteins can be modified to treat the diseases better but anyone that wants to work on MANF or anything similar to it has to go through AMBS. There's a reason why Hermo Pharma challenged these patents.
In their own words:
"Their patent covers all sequences with 90% homology to MANF (182 amino acid protein --> variation in 18 amino acid residues allowed, 20 options for each position --> you do the math; the result is an astronomical number of variants!). According to the patent law this causes "an undue burden" to anyone who would like to test these variants for activity. This is the explanation why we have challenged the EPO granted patent on MANF for Amarantus."
I'm putting my money with the co-founder of Amgen, not some college kids on this board with $3,000 who are naive enough to think they have any power over a stock.
I predict it closes above $0.10 tomorrow and you will be wrong once again.
Too many positives to ignore. We have a HUGE upcoming catalyst just 7 trading days away.
Gerald Commissiong:
"Hello. I'd like to welcome Dr. Joseph Rubinfeld, co-founder of Amgen, who will be presenting about the commercial opportunities of our flagship drug, MANF. "
$0.20 to $0.25 by 1/8/13 is my official call, barring a partnership / licensing deal which would put the top at much higher. Let's take baby steps first before we call it the next Amgen. I think we ultimately hit $100 Million market cap. Too many positives here to outweigh everything else:
(1) AMGEN co-founder presents on 1/8 and has already called it potentially the biggest success he has ever seen.
(2) Patent protection is absolutely huge.
(3) Already producing better results than other drugs in the Neurotrophic Factor category of drugs which all have gotten at least $150 Million funding each. Again, market cap is $17 Million right now. HELLOOOOO!!!
People sell for a variety of reasons. The real winners will be the ones who are patient like Smoke_em, lewsogge, aewilliamson, and me. We have all been here a while and know the story in and out.
$100 Million market cap is what I believe we will see, which equates to $0.45 or so. That has been my target all along. That would be a 100 bagger from the bottom. This is one of those epic stocks that you see only once every 5 years or so.
Anyone selling will regret it. I understand the reasons for selling...nothing wrong with locking in gains. But the big money will be made buying and sitting. I picked up another 500k today around $0.076. Sitting on 6.5 Million. The conferences on 1/8 and 1/9 will be absolutely huge for this company. Having the co-founder of a $67 Billion company speaking on your behalf about the commercial opportunities of your drug is mind bogglingly positive.
Wake me up when this hits $100 Million market cap. I've been saying it for 6 weeks now and I will say it again. Those people who are patient enough to wait out these dips will be very wealthy when it hits $0.40+.
Here are the things to keep in mind as people bash it:
(1) 1/8/13 conference will be a major catalyst. Having the founder of a $67 billion company presenting on your behalf about the commercial opportunities of your drug should add just a teeny weeny amount of credibility.
(2) The co-founder of Amgen said MANF "could be one of the biggest successes that I have ever seen." This is a 79 year old man that has seen a lot of things in his career.
(3) Hermo Pharma, a MJFF grant recipient and VC backed, felt compelled to challenge the company's MANF patents...why? Read this article below:
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
In their own words:
"Their patent covers all sequences with 90% homology to MANF (182 amino acid protein --> variation in 18 amino acid residues allowed, 20 options for each position --> you do the math; the result is an astronomical number of variants!). According to the patent law this causes "an undue burden" to anyone who would like to test these variants for activity. This is the explanation why we have challenged the EPO granted patent on MANF for Amarantus."
(4) AMBS is only worth $17 Million right now. It is producing far better results than GDNF which was purchased by Amgen for $250 Million.
(5) While AMBS hasn't done head to head comarisons with Neurturin, Neurturin is being developed as a gene therapy by Ceregene and has multiple published studies comparing it with GDNF. One thing of note with Neurturin is that it has higher heparin binding, and thus less volume of diffusion in the brain. As we know GDNF had issues with volume of diffusion in the brain and MANF has been proven to have much better diffusion volume. Ceregene has plowed $150 Million into Neurturin.
Do the math. Listen to people that know the science like Dr. Rubinfeld and the dozens of other scientists that have worked on MANF over the past 10 years (just google MANF if you don't believe me). AMBS has patent protection on MANF and anything that has a 90% homology (i.e., similarity) to MANF. These proteins can be modified to treat the diseases better but anyone that wants to work on MANF or anything similar to it has to go through AMBS. There's a reason why Hermo Pharma challenged these patents. Anyone that is patient enough to sit through these pockets of weakness will make out like bandits. I fully expect a funding partnership with a licensing deal very soon.
Why is the Co-Founder of Amgen Here?
If you have any doubts this is all you need to ask yourself. We're talking about the freaking co-founder of Amgen, a $67 Billion company. He previously said: "I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen." And he's presenting on the potential for commercial opportunities of MANF at a conference in January. For doubters: Do you really think they're going to present bad data in front of a conference of VC and angel investors and big pharma companies that are paying $400 to attend?
Then ask yourself why another biotech firm in the same exact field with MJFF grants was compelled to challenge their patents and even stated that the patent protection is so broad that is causes "an undue burden on anyone trying to test MANF and any of its variants".
$28 Million market cap for all of this? Puhlease. This is a friggin freight train heading higher. Anyone trying to flip it for pennies will be very sorry when it runs to $0.40+ and they're left waiting for a dip. It's going to be a $100 Million+ company very soon.
My money is with the co-founder of Amgen...
Stars are aligned for a move to $0.40. The market cap is still way too small for this given:
+Money poured into GDNF (which has had worse results than MANF) ~ $250 Million
+Money poured into Neurturin ~ $150 Million
+Patent protection - upheld in court vs Hermo Pharma, a VC backed and MJFF funded biotech firm
+Founder of Amgen believes it could be the biggest success he has ever seen.
When this hits $100 Million market cap you, me, aewilliamson, and lewsogge will make out like bandits. It seems like we are a select group of people who are patient enough to wait out these dips. I know you have more shares than I do but not by a ton...we will be very wealthy when it hits $0.40+
Why is the Co-Founder of Amgen Here?
If you have any doubts this is all you need to ask yourself. We're talking about the freaking co-founder of Amgen, a $67 Billion company. He previously said: "I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen." And he's presenting on the potential for commercial opportunities of MANF at a conference in January. For doubters: Do you really think they're going to present bad data in front of a conference of VC and angel investors and big pharma companies that are paying $400 to attend?
Then ask yourself why another biotech firm in the same exact field with MJFF grants was compelled to challenge their patents and even stated that the patent protection is so broad that is causes "an undue burden on anyone trying to test MANF and any of its variants".
$24 Million market cap for all of this? Puhlease. This is a friggin freight train heading higher. Anyone trying to flip it for pennies will be very sorry when it runs to $0.40+ and they're left waiting for a dip. It's going to be a $100 Million+ company very soon. The longs like lewsogge, smoke_em, and me will be rewarded heavily. This is an epic stock. One of those ones that runs 200 times higher than the bottom and rewards the longs who have the patience to hold on immensely. Think 200 x 0.005...$1.00.
My money is with the co-founder of Amgen...and not some naive college kids with $3,000 to their name thinking they have some sort of power over the stock.
wait but i thought you said it was going to $0.03? LOL
The market cap is still tiny. That's all that matters and it is worth repeating. People will sell for a variety of reasons...most likely because they either had a great entry point or a much higher entry point and just want to get out. Most investors are impatient. I would drop any conspiracy theories because there is no conspiracy going on.
I would pay a little more attention to the comments from the co-founder of Amgen (i.e., "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen.") and think to yourself why Hermo Pharma felt compelled to challenge their MANF patents. MANF is producing much better results than GDNF produced at this stage and GDNF was purchased for over $250 Million AT THIS STAGE of testing.
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
AMBS is only worth $23 Million right now.
Versus $250 Million.
Do the math. Listen to people that know the science like Dr. Rubinfeld and the dozens of other scientists that have worked on MANF over the past 10 years (just google MANF if you don't believe me). AMBS has patent protection on MANF and anything that has a 90% homology (i.e., similarity) to MANF. These proteins can be modified to treat the diseases better but anyone that wants to work on MANF or anything similar to it has to go through AMBS. There's a reason why Hermo Pharma challenged these patents.
In their own words:
"Their patent covers all sequences with 90% homology to MANF (182 amino acid protein --> variation in 18 amino acid residues allowed, 20 options for each position --> you do the math; the result is an astronomical number of variants!). According to the patent law this causes "an undue burden" to anyone who would like to test these variants for activity. This is the explanation why we have challenged the EPO granted patent on MANF for Amarantus."
Wow Awesome Interview with Michael J Fox:
http://www.katiecouric.com/features/michael-j-fox-on-living-with-parkinsons/
The 1/8/13 conference will be a major catalyst. Having the founder of a $67 billion company presenting on your behalf about the commercial opportunities of your drug should add just a teeny weeny amount of credibility.
Ask yourself 2 simple questions:
(1) Why is the co-founder of Amgen saying MANF "could be one of the biggest successes that I have ever seen."? This is a 79 year old man that has seen a lot of things in his career.
(2) Why did Hermo Pharma, a MJFF grant recipient and VC backed, feel compelled to challenge the company's MANF patents?
MANF is producing much better results than GDNF produced at this stage and GDNF was purchased for over $250 Million AT THIS STAGE of testing.
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
AMBS is only worth $24 Million right now.
Versus $250 Million.
Do the math. Listen to people that know the science like Dr. Rubinfeld and the dozens of other scientists that have worked on MANF over the past 10 years (just google MANF if you don't believe me). AMBS has patent protection on MANF and anything that has a 90% homology (i.e., similarity) to MANF. These proteins can be modified to treat the diseases better but anyone that wants to work on MANF or anything similar to it has to go through AMBS. There's a reason why Hermo Pharma challenged these patents.
In their own words:
"Their patent covers all sequences with 90% homology to MANF (182 amino acid protein --> variation in 18 amino acid residues allowed, 20 options for each position --> you do the math; the result is an astronomical number of variants!). According to the patent law this causes "an undue burden" to anyone who would like to test these variants for activity. This is the explanation why we have challenged the EPO granted patent on MANF for Amarantus."
I'm putting my money with the co-founder of Amgen, not some college kids on this board with $3,000 who are naive enough to think they have any power over a stock.
The 1/8/13 conference will be a major catalyst. Having the founder of a $67 billion company presenting on your behalf about the commercial opportunities of your drug should add just a teeny weeny amount of credibility.
Ask yourself 2 simple questions:
(1) Why is the co-founder of Amgen saying MANF "could be one of the biggest successes that I have ever seen."? This is a 79 year old man that has seen a lot of things in his career.
(2) Why did Hermo Pharma, a MJFF grant recipient and VC backed, feel compelled to challenge the company's MANF patents?
MANF is producing much better results than GDNF produced at this stage and GDNF was purchased for over $250 Million AT THIS STAGE of testing.
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
AMBS is only worth $24 Million right now.
Versus $250 Million.
Do the math. Listen to people that know the science like Dr. Rubinfeld and the dozens of other scientists that have worked on MANF over the past 10 years (just google MANF if you don't believe me). AMBS has patent protection on MANF and anything that has a 90% homology (i.e., similarity) to MANF. These proteins can be modified to treat the diseases better but anyone that wants to work on MANF or anything similar to it has to go through AMBS. There's a reason why Hermo Pharma challenged these patents.
In their own words:
"Their patent covers all sequences with 90% homology to MANF (182 amino acid protein --> variation in 18 amino acid residues allowed, 20 options for each position --> you do the math; the result is an astronomical number of variants!). According to the patent law this causes "an undue burden" to anyone who would like to test these variants for activity. This is the explanation why we have challenged the EPO granted patent on MANF for Amarantus."
I'm putting my money with the co-founder of Amgen, not some college kids on this board with $3,000 who are naive enough to think they have any power over a stock.
The market cap is so tiny on AMBS. That's all that matters and it is worth repeating. People will sell for a variety of reasons...most likely because they either had a great entry point or a much higher entry point and just want to get out. Most investors are impatient. I would drop any conspiracy theories because there is no conspiracy going on.
I would pay a little more attention to the comments from the co-founder of Amgen (i.e., "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen.") and think to yourself why Hermo Pharma felt compelled to challenge their MANF patents. MANF is producing much better results than GDNF produced at this stage and GDNF was purchased for over $250 Million AT THIS STAGE of testing.
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
AMBS is only worth $22 Million right now.
Versus $250 Million.
Do the math. Listen to people that know the science like Dr. Rubinfeld and the dozens of other scientists that have worked on MANF over the past 10 years (just google MANF if you don't believe me). AMBS has patent protection on MANF and anything that has a 90% homology (i.e., similarity) to MANF. These proteins can be modified to treat the diseases better but anyone that wants to work on MANF or anything similar to it has to go through AMBS. There's a reason why Hermo Pharma challenged these patents.
In their own words:
"Their patent covers all sequences with 90% homology to MANF (182 amino acid protein --> variation in 18 amino acid residues allowed, 20 options for each position --> you do the math; the result is an astronomical number of variants!). According to the patent law this causes "an undue burden" to anyone who would like to test these variants for activity. This is the explanation why we have challenged the EPO granted patent on MANF for Amarantus."
Why is the Co-Founder of Amgen Here?
If you have any doubts this is all you need to ask yourself. We're talking about the freaking co-founder of Amgen, a $67 Billion company. He previously said: "I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen." And he's presenting on the potential for commercial opportunities of MANF at a conference in January. For doubters: Do you really think they're going to present bad data in front of a conference of VC and angel investors and big pharma companies that are paying $400 to attend?
Then ask yourself why another biotech firm in the same exact field with MJFF grants was compelled to challenge their patents and even stated that the patent protection is so broad that is causes "an undue burden on anyone trying to test MANF and any of its variants".
$17 Million market cap for all of this? Puhlease. This is a friggin freight train heading higher. Anyone trying to flip it for pennies will be very sorry when it runs to $0.40+ and they're left waiting for a dip. It's going to be a $100 Million+ company very soon.
My money is with the co-founder of Amgen...
The 1/8/13 conference will be a major catalyst. Having the founder of a $67 billion company presenting on your behalf about the commercial opportunities of your drug should add just a teeny weeny amount of credibility.
Ask yourself 2 simple questions:
(1) Why is the co-founder of Amgen saying MANF "could be one of the biggest successes that I have ever seen."? This is a 79 year old man that has seen a lot of things in his career.
(2) Why did Hermo Pharma, a MJFF grant recipient and VC backed, feel compelled to challenge the company's MANF patents?
MANF is producing much better results than GDNF produced at this stage and GDNF was purchased for over $250 Million AT THIS STAGE of testing.
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
AMBS is only worth $17 Million right now.
Versus $250 Million.
Do the math. Listen to people that know the science like Dr. Rubinfeld and the dozens of other scientists that have worked on MANF over the past 10 years (just google MANF if you don't believe me). AMBS has patent protection on MANF and anything that has a 90% homology (i.e., similarity) to MANF. These proteins can be modified to treat the diseases better but anyone that wants to work on MANF or anything similar to it has to go through AMBS. There's a reason why Hermo Pharma challenged these patents.
In their own words:
"Their patent covers all sequences with 90% homology to MANF (182 amino acid protein --> variation in 18 amino acid residues allowed, 20 options for each position --> you do the math; the result is an astronomical number of variants!). According to the patent law this causes "an undue burden" to anyone who would like to test these variants for activity. This is the explanation why we have challenged the EPO granted patent on MANF for Amarantus."
I'm putting my money with the co-founder of Amgen, not some college kids on this board with $3,000 who are naive enough to think they have any power over a stock.
Excellent Dr. Rubinfeld interview:
From 10 yrs ago to give you a sense of what he brings to the table:
http://www.twst.com/interview/8279
Again, I believe he will help AMBS strike an in licensing deal and also get help them get substantial funding. I believe AMBS should be worth at least $75 mill right now (about 4 to 5 times current value). I'm basing this on relative valuation for GDNF with a substantial discount and on patent protection...remember a partner from Hermo Pharma (VC backed and MJFF funded company that challenged the company's MANF patents and lost) was quoted as saying that the company's MANF patents "cause an undue burden" on anyone trying to test MANF or anything with a 90% homology (ie similarity) to it.
http://m.seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
Don't listen to college kids like solantey with $3000 to their name warning of impending doom because they're naive enough to think they can manipulate a stock. They sold and want back in at lower prices...they see the writing on the wall. They made a mistake. Those of us that have been patient enough to hold and continue to hold will reap massive benefits. It won't be easy to hold with huge gains but the valuation is way too low.
Absolutely...MANF is known to deliver better to the brain than due to a variety of reasons but primarily due to the structure of the protein. I can send you some publications on it or you can just google MANF publications and read up on it. GDNF was halted (it's back in stage 2) because it dispersed too widely when it entered the cranium upon injection, rendering a placebo effect and also because delivery methods were poor. Delivery methods have been vastly improved since GdNF was halted (which is why Prof Gill at bristol Univ has brought it back for trials) and MANF's dispersion characteristics are much more favorable.
Excellent Rubinfeld interview:
From 10 yrs ago to give you a sense of what he brings to the table:
http://www.twst.com/interview/8279
Again, I believe he will help AMBS strike an in licensing deal and also get help them get substantial funding. I believe AMBS should be worth at least $75 mill right now (about 4 to 5 times current value). I'm basing this on relative valuation for GDNF with a substantial discount and on patent protection...remember a partner from Hermo Pharma (VC backed and MJFF funded company that challenged the company's MANF patents and lost) was quoted as saying that the company's MANF patents "cause an undue burden" on anyone trying to test MANF or anything with a 90% homology (ie similarity) to it.
http://m.seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
Yes and much better results than GDNF at this stage, which was owned by a company purchased by Amgen for $250 mill at same stage. Amgen co founder Joseph Rubinfeld left Amgen in 1990 but he was familiar with GDNF and has callend MANF a potential blockbuster drug and said it could be the biggest success he has ever seen. He is a very well connected guy and is speaking about commercial opportunities for MAnF in other diseases on 1/8/13.
I believe he will help AMBS strike an in licensing deal and also get help them get substantial funding. I believe AMBS should be worth at least $75 mill right now (about 4 to 5 times current value).
Here is a good interview Rubinfeld did 10 yrs ago to give you a sense of what he brings to the table:
http://www.twst.com/interview/8279
The 1/8/13 conference will be a major catalyst. Having the founder of a $67 billion company presenting on your behalf about the commercial opportunities of your drug should add just a teeny weeny amount of credibility.
Ask yourself 2 simple questions:
(1) Why is the co-founder of Amgen saying MANF "could be one of the biggest successes that I have ever seen."? This is a 79 year old man that has seen a lot of things in his career.
(2) Why did Hermo Pharma, a MJFF grant recipient and VC backed, feel compelled to challenge the company's MANF patents?
MANF is producing much better results than GDNF produced at this stage and GDNF was purchased for over $250 Million AT THIS STAGE of testing.
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
AMBS is only worth $17 Million right now.
Versus $250 Million.
Do the math. Listen to people that know the science like Dr. Rubinfeld and the dozens of other scientists that have worked on MANF over the past 10 years (just google MANF if you don't believe me). AMBS has patent protection on MANF and anything that has a 90% homology (i.e., similarity) to MANF. These proteins can be modified to treat the diseases better but anyone that wants to work on MANF or anything similar to it has to go through AMBS. There's a reason why Hermo Pharma challenged these patents.
In their own words:
"Their patent covers all sequences with 90% homology to MANF (182 amino acid protein --> variation in 18 amino acid residues allowed, 20 options for each position --> you do the math; the result is an astronomical number of variants!). According to the patent law this causes "an undue burden" to anyone who would like to test these variants for activity. This is the explanation why we have challenged the EPO granted patent on MANF for Amarantus."
I'm putting my money with the co-founder of Amgen, not some college kids on this board with $3,000 who are naive enough to think they have any power over a stock.
Solantey is right going much higher.
Love how this is backing and filling. Looks like we keep working through short term traders and are leaving ourselves with really strong hands. Anyone that sells comes on this board and bashes hoping for lower prices only to see it go higher and higher, which will leave them with chasing the stock.
Textbook breakout trading and the best part is it isn't having that euphoric spike yet like last time...when that happens we could see $0.20+.
Let's see if we can break above $0.069 today. Good luck players.
Great post Solantey - $0.20 is just a blink away.
By the way, we now know your true colors. What ever happened to having some integrity in life? Just admit it that you're worried you made a mistake selling and you hope it dips so you can buy more? I'm sure we would all appreciate it a little more and when you're older you will be able to look back on life with some more pride that you were honest.
Like I said I'm putting my money with the co-founder of Amgen who happens to think MANF is a blockbuster and the biggest success he has ever seen. I like listening to people with knowledge and experience, not college kids with $3,000 to their name.
Solantey is right going to $1.00 or more.
FYI: We will just keep responding to your bullish comments to show people your true colors
Wow. Great post. And to think AMBS owns patents on MANF and anything with a 90% homology (i.e., similarity) to it. Probably a good reason why Hermo Pharma challenged their patents: they see the writing on the wall.
I agree great point!
We will just keep responding to your bullish comments to show people your true colors
A close above $0.069 will be a new closing high since October. We have bumped up against this 4 times now and formed a cup and handle. The breakout projects to 0.11 initially.
I always look at closing prices instead of the intraday noise.
Again, $14 Million market cap for a company with patent protection on a drug that has had much better results than GDNF which was owned by a company bought out for $250 Million and a drug that the co-founder of Amgen said could be a blockbuster makes me think there is much more upside than 0.11. That would only be a market cap of around $25 million.
The jan 8th conference could provide a massive spark. Major exposure there especially with the Amgen founder presenting on MANF's commercial potential outside of PD. I think we come away with a partnership and licensing deal (with an upfront payment and milestone payments) within a month after that.
Why is the Co-Founder of Amgen Here?
If you have any doubts this is all you need to ask yourself. We're talking about the freaking co-founder of Amgen, a $67 Billion company. He previously said: "I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen." And he's presenting on the potential for commercial opportunities of MANF at a conference in January. For doubters: Do you really think they're going to present bad data in front of a conference of VC and angel investors and big pharma companies that are paying $400 to attend?
Then ask yourself why another biotech firm in the same exact field with MJFF grants was compelled to challenge their patents and even stated that the patent protection is so broad that is causes "an undue burden on anyone trying to test MANF and any of its variants".
$14 Million market cap for all of this? Puhlease. This is a friggin freight train heading higher. Anyone trying to flip it for pennies will be very sorry when it runs to $0.40+ and they're left waiting for a dip. It's going to be a $100 Million+ company very soon.
My money is with the co-founder of Amgen...
I could care less about the MJFF grants going forward. I agree that the grants are good but this company is setting itself up for a partnership deal with a larger biopharma company. The writing is on the wall. Rubinfeld and the other senior execs from Bayer, Bristol Myers and Pfizer that are on the board will bring a deal to them. A partnership with a bigger pharma company that includes a license deal will allow them to fund the trials at the partner's expense while giving up a license / royalty on sales.
The $13 Million market cap is a joke. MANF is currently producing significantly better results than GDNF was at this stage of testing when the company that owned it was bought out for $250 Million. I believe AMBS will be at a $100 Million market cap within a year and probably within 6 months.
People who are still doubting this need to ask themselves a few questions:
(1) Why is the co-founder of Amgen wasting his time here? This is a guy with a ridiculously impressive resume. Co-Founder of Amgen, founder of Supergen, invented Amoxicillin.
(2) Why is he presenting along with the CSO, John Commissiong, at a biotech conference known for bringing VC and bigger pharma investors to biotech startups?
(3) Why did the co-Founder of Amgen state that MANF could be the biggest success he has ever seen in his career?
(4) And why did Hermo Pharma, a VC backed and MJFF funded biotech in the same exact field as AMBS, challenge their patents? Why would they say that their patent protection is too broad and causes an undue burden on anyone trying to test for any variant of MANF?
Hmmmm.
Again, I'm not going to waste my time listening to some college kids on this board with their $3,000 in life savings trying to bash the stock. Get lost. I'd rather spend my time listening to guys like the co-founder of Amgen. I know it's crazy but I think they have just a little more knowledge about this patent protected drug.
Get ready for the fireworks leading into the January presentation. It's going to be very exciting. I get the feeling this is being accumulated heavily.